Research Article
The Biological Metallic versus Metallic Solution in Treating Periprosthetic Femoral Fractures: Outcome Assessment
Table 2
Patients’ comorbidity.
| | | PS (%) | PSS number (%) |
| | Comorbidity | | | | Cardiovascular diseases | 6 (75%) | 5 (71.42%) | | Stroke | 4 (50%) | 1 (14.29%) | | Respiratory diseases | 5 (62.5%) | 6 (85.71%) | | Nefro-urologic diseases | 5 (62.5%) | 2 (28.57%) | | Diabetes mellitus | 4 (50%) | 6 (85.71%) | | Rheumatic diseases | 4 (50%) | 7 (100%) | | Parkinson’s disease | 1 (12.5%) | 2 (28.57%) | | Smokers | 1 (12.5%) | 3 (42.86%) | | Use of steroids | 7 (87.5%) | 7 (100%) | | Number of comorbidities for patient | | | | 1 | 1 (12.5%) | 1 (14.29%) | | 2 | 2 (25%) | 1 (14.29%) | | ≥3 | 5 (62.5%) | 5 (71.42%) |
|
|
